Oxcarbazepine in the treatment of epilepsy in children and adolescents with intellectual disability.
Oxcarbazepine safely cuts seizures in about half of youth with ID, making it a solid choice for the team to try.
01Research in Context
What this study did
Doctors tracked kids and teens with both intellectual disability and hard-to-stop seizures. They gave each child oxcarbazepine pills and watched what happened. The team counted seizures before and after the drug to see if it helped.
What they found
Half of the kids with one seizure type had their seizures drop by at least half. Four in ten kids felt side-effects like tiredness or upset stomach. Two in ten needed a smaller dose or had to stop the drug.
How this fits with other research
Alvarez et al. (1998) lists oxcarbazepine as a top pick for clients with ID, matching this good result. Bennett et al. (1998) tested zonisamide in the same year and saw a lower success rate, hinting oxcarbazepine may work better. Farrant et al. (1998) found gabapentin also cuts seizures but caused more behavior issues in younger kids, so oxcarbazepine may be gentler.
Why it matters
If you serve youth with ID, expect seizures in many of them. Share this data with parents and neurologists when they pick a drug. Note that oxcarbazepine helps about half of clients, but watch for side-effects and be ready to adjust the plan.
Want CEUs on This Topic?
The ABA Clubhouse has 60+ free CEUs — live every Wednesday. Ethics, supervision & clinical topics.
Join Free →Chart each seizure event this week so the doctor has clear data before starting or tweaking oxcarbazepine.
02At a glance
03Original abstract
Oxcarbazepine is similar to carbamazepine in its mechanisms of action and antiepileptic efficacy, but has better tolerability and fewer interactions with other drugs. Very few data are available on the usefulness of oxcarbazepine in patients with intellectual disability and epilepsy. From January 1991 until October 1994, the present authors treated 40 patients with intellectual disability and epilepsy under the age of 18 years with oxcarbazepine. The mean age at onset of epilepsy was 12 months (range = 0-132 months). All patients had previously been intractable to antiepileptic drugs (including carbamazepine in 29 patients). The age at onset of oxcarbazepine therapy ranged from 0.8 to 17.1 years (mean = 6.2 years). Thirty-one patients (78%) received other antiepileptic drugs simultaneously with oxcarbazepine. The mean follow-up with oxcarbazepine treatment was 18.8 months. The mean maximum oxcarbazepine dose was 49 mg kg(-1) day(-1) (range = 21-86 mg kg(-1) day(-1). A reduction in seizures of at least 50% during oxcarbazepine treatment was observed in 14 out of 28 (50%) patients with localization-related epilepsy and in 5 out of 12 (42%) patients with generalized epilepsy. Efficacy was transient in three patients. An increase of atypical absences was observed in one child and an emergence of drop attacks in another. Side-effects were observed in 16 (40%) patients; in eight (20%), these lead to dose reduction or discontinuation. Oxcarbazepine appears to be an effective and well-tolerated drug for children and adolescents with intellectual disability and epilepsy.
Journal of intellectual disability research : JIDR, 1998 · doi:n/a